Glenmark Pharmaceuticals Limited (GLENMARK) announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its formulations manufacturing facility in Goa, India, with a Voluntary Action Indicated (VAI) status. The inspection was conducted from June 22, 2026, to June 30, 2026. This report is a significant milestone for the company as it underscores the quality and compliance of its manufacturing processes.

Inspection Highlights

The U.S. FDA’s inspection team evaluated various aspects of the manufacturing facility, including production protocols, quality control measures, and overall facility management. Notably, the FDA highlighted areas that require voluntary actions to address certain observations. This VAI classification indicates that while the facility meets most regulatory standards, there are specific areas needing improvement.

Company’s Response

Glenmark Pharmaceuticals Limited is committed to addressing the observations mentioned in the report. The company plans to implement corrective and preventive actions to ensure full compliance with FDA standards. This proactive approach will help Glenmark maintain its reputation for high-quality pharmaceutical manufacturing.

As a result, Glenmark Pharmaceuticals Limited continues to focus on innovation and accessibility, aiming to deliver affordable and high-quality medicines globally. The company’s robust manufacturing infrastructure and commitment to excellence will drive its ongoing success and compliance with international regulatory standards.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Glenmark rises 12.9% over three months, with buying pressure holding steady. The PEG of 0.59 signals undervaluation relative to growth. It is a potential re-rating candidate. Revenue grows at 13.5% and profits at 66.1% CAGR. The market consistently rewards this kind of compounding. The stock trades at 90% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.59 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.

Hikal Limited (HIKAL) has marked a significant milestone with the successful commercial production of its Personal Care products from its new cGMP-compliant, multipurpose manufacturing facility in Panoli, Gujarat. This new facility represents Hikal’s formal entry into the commercial-scale supply for the global beauty and personal care industry, aligning with the company’s broader strategy of building new, high-value growth platforms alongside its established Pharmaceuticals, Crop Protection, and Animal Healthcare businesses.

Strategic Entry into Personal Care

As part of its strategic commitment to this new segment, Hikal repurposed an existing manufacturing asset at Panoli to serve the evolving needs of the global beauty and personal care industry. The facility has recently commenced commercial production and successfully manufactured its first production batches. Product samples have been validated with customers, and the company has received encouraging feedback, resulting in a positive market pull for its product portfolio.

Focus on Beauty & Personal Care

Hikal’s initial focus within Personal Care is on the Beauty & Personal Care segment, particularly the skin care category, where demand continues to grow globally. The company has built a strong portfolio of second-generation UV filters, offering enhanced performance and closer alignment with evolving consumer preferences and tightening regulatory requirements across key markets. These products are undergoing approvals by its global customers, as part of Hikal’s continued strategy of portfolio diversification beyond its core Pharma and Crop Protection segments.

“Personal Care represents the kind of long-term opportunity we look for. We’ve applied the same disciplined approach that built our Pharmaceuticals and Crop Protection businesses, deep customer partnerships, rigorous quality systems, and patient capital investment, to a new category where global demand for specialty skincare ingredients is accelerating. Commissioning the Panoli facility, manufacturing our first production batches, and securing positive customer feedback points towards the growth of the business in the coming years,” said Sameer Hiremath, Vice Chairman & Managing Director, Hikal Limited.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hikal Limited

Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 61% of its 52-week range with RSI at 53. In other words, neither side has a clear edge right now. Price climbs recently despite -5.4% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Hikal Limited.

Park Medi World Limited (NSE: PARKHOSPS) has been recognised with three honours at the prestigious Healthcare Pioneers of Delhi 2026 awards. The accolades were presented by Smt. Rekha Gupta, Hon’ble Chief Minister of Delhi, at The Imperial Hotel, Janpath, New Delhi on 20th September 2026. The recognition highlights the Group’s commitment to clinical outcomes, advanced medical technology, and expanding presence across North India.

Lifetime Achievement Award

Dr. Ajit Gupta, Founder & Chairman, received the Lifetime Achievement Award. This honour reflects his long-standing dedication to healthcare excellence.

Future Healthcare Leader of the Year

Dr. Ankit Gupta, Managing Director, was named Future Healthcare Leader of the Year. This recognition underscores his leadership in scaling capacity and investing in advanced medical technology.

Excellence in Advanced Medical Technology & Patient Care

Park Group of Hospitals was awarded Excellence in Advanced Medical Technology & Patient Care. This accolade highlights the Group’s commitment to providing high-quality, affordable healthcare services.

As Park Medi World Limited continues to expand its network, it aims to build a dependable, technology-enabled healthcare ecosystem that serves both metropolitan and regional communities across North India. For more information, visit www.parkhospital.in.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Park Medi World Limited

Park Medi World Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Park holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG stands at 7.91 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -0.7% in three months on 9.6% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Park Medi World Limited.